Madrigal Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
MDGL Madrigal Pharmaceuticals Inc
ADBE Adobe Inc
FATP Fat Projects Acquisition Corp
LGVC LAMF Global Ventures I Corp
SECO Secoo Holding Ltd
SGBXV Safe & Green Holdings Corp
CAH Cardinal Health Inc
CHEK Check Cap Ltd
NMG Nouveau Monde Graphite Inc
HYZN Hyzon Motors Inc
Go

Health Care : Biotechnology | Small Cap Value

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a proprietary, liver-directed, selective thyroid hormone receptor-B (THR-B), agonist being developed as a once-daily oral pill for the treatment of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).

Price: Delayed
$150.94

Day's Change: 0.00 (0.00%)

Bid: --

Ask: --

B/A Size: --

Day's High: --

Day's Low: --

Volume (Light) Today's volume of 22,427 shares is on pace to be much lighter than MDGL's 10-day average volume of 552,504 shares.: 22,427

September 14, 2023
4:30 pm ET	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)(Globe Newswire)
6:56 am ET	Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States.(Zacks)
September 13, 2023
9:10 am ET	Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis(Globe Newswire)
September 11, 2023
12:09 pm ET	Tesla and Canopy Growth stocks surge, RTX and J.M. Smucker shares fall, and other stocks on the move By MarketWatch Twinkies parent Hostess Brands' stock soars, J.M. Smucker shares drop, as companies announce $5.6 billion merger deal Here are some of the bigger and more-active movers on Monday: (MarketWatch)
8:32 am ET	Madrigal Pharmaceuticals shares fall after new CEO named Shares of Madrigal Pharmaceuticals Inc. (MDGL) fell more than 7% premarket on Monday after the company appointed Bill Sibold, a former Sanofi (SAN.FR) executive, as its new CEO. Sibold succeeds Dr. Paul Friedman, the company's CEO since 2016...(MarketWatch)
7:00 am ET	Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer(Globe Newswire)
August 08, 2023
8:00 am ET	Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results(Globe Newswire)
July 17, 2023
8:00 am ET	Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis(Globe Newswire)
July 10, 2023
8:32 am ET	Viking Therapeutics (VKTX) Surges 64% Year to Date: Here's Why The rising share price of Viking Therapeutics (VKTX) is attributable to the successful development of the company's pipeline candidates, targeting diseases like NASH and obesity.(Zacks)
June 30, 2023
12:29 pm ET	Madrigal Pharmaceuticals' stock up 5% as company starts rolling submission for FDA approval of NASH treatment Madrigal Pharmaceuticals Inc.'s stock (MDGL) rose 5% Friday after the company said it has started a rolling submission of a New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval of its resmetirom as a...(MarketWatch)
8:00 am ET	Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis(Globe Newswire)
June 27, 2023
8:11 am ET	Weight-loss drugs in development aim to replace injections with pills By Eleanor Laise Promising results for investigational weight-loss treatments and new screening recommendations for fatty-liver disease emerge from diabetes conference (MarketWatch)
April 19, 2023
10:36 am ET	Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector. (Zacks)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and